Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Oncology Today with Dr Neil Love
00:00
Somerotoclax: a more potent BCL2 inhibitor
Tam explains somerotoclax's tighter BCL2 binding, activity against venetoclax-resistance mutations, and favorable toxicity.
Play episode from 10:07
Transcript
